1001 related articles for article (PubMed ID: 11059567)
41. Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment.
Soloway MS; Briggman V; Carpinito GA; Chodak GW; Church PA; Lamm DL; Lange P; Messing E; Pasciak RM; Reservitz GB; Rukstalis DB; Sarosdy MF; Stadler WM; Thiel RP; Hayden CL
J Urol; 1996 Aug; 156(2 Pt 1):363-7. PubMed ID: 8683680
[TBL] [Abstract][Full Text] [Related]
42. Decision curve analysis assessing the clinical benefit of NMP22 in the detection of bladder cancer: secondary analysis of a prospective trial.
Barbieri CE; Cha EK; Chromecki TF; Dunning A; Lotan Y; Svatek RS; Scherr DS; Karakiewicz PI; Sun M; Mazumdar M; Shariat SF
BJU Int; 2012 Mar; 109(5):685-90. PubMed ID: 21851550
[TBL] [Abstract][Full Text] [Related]
43. [Evaluation of usefulness of urinary nuclear matrix protein 22 (NMP22) in the detection of urothelial transitional cell carcinoma].
Miyoshi Y; Matsuzaki J; Miura T
Hinyokika Kiyo; 2001 Jun; 47(6):379-83. PubMed ID: 11496392
[TBL] [Abstract][Full Text] [Related]
44. Pathologic features of bladder tumors after nephroureterectomy or segmental ureterectomy for upper urinary tract transitional cell carcinoma.
Raman JD; Sosa RE; Vaughan ED; Scherr DS
Urology; 2007 Feb; 69(2):251-4. PubMed ID: 17320658
[TBL] [Abstract][Full Text] [Related]
45. Can urine bound diagnostic tests replace cystoscopy in the management of bladder cancer?
Wiener HG; Mian C; Haitel A; Pycha A; Schatzl G; Marberger M
J Urol; 1998 Jun; 159(6):1876-80. PubMed ID: 9598479
[TBL] [Abstract][Full Text] [Related]
46. [The study of relationship between nuclear metrix protein 22 urinary level and the grade and stage of bladder transitional cell carcinoma].
Xin DQ; You R; Ding Y; Liu LQ; Na YQ
Zhonghua Wai Ke Za Zhi; 2006 May; 44(10):681-3. PubMed ID: 16784679
[TBL] [Abstract][Full Text] [Related]
47. Evaluation of urine CYFRA 21-1 for the detection of primary and recurrent bladder carcinoma.
Nisman B; Barak V; Shapiro A; Golijanin D; Peretz T; Pode D
Cancer; 2002 Jun; 94(11):2914-22. PubMed ID: 12115379
[TBL] [Abstract][Full Text] [Related]
48. Suspicious urine cytology (class III) in patients with bladder cancer: should it be considered as negative or positive?
Raitanen MP; Aine RA; Kaasinen ES; Liukkonen TJ; Kylmälä TM; Huhtala H; Tammela TL;
Scand J Urol Nephrol; 2002; 36(3):213-7. PubMed ID: 12201938
[TBL] [Abstract][Full Text] [Related]
49. Results of Bard BTA test in monitoring patients with a history of transitional cell cancer of the bladder.
Ianari A; Sternberg CN; Rossetti A; Van Rijn A; Deidda A; Giannarelli D; Pansadoro V
Urology; 1997 May; 49(5):786-9. PubMed ID: 9145993
[TBL] [Abstract][Full Text] [Related]
50. Comparison of the sensitivity and specificity of urine cytology, urinary nuclear matrix protein-22 and multitarget fluorescence in situ hybridization assay in the detection of bladder cancer.
Kehinde EO; Al-Mulla F; Kapila K; Anim JT
Scand J Urol Nephrol; 2011 Mar; 45(2):113-21. PubMed ID: 21091091
[TBL] [Abstract][Full Text] [Related]
51. Urinary levels of soluble e-cadherin in the detection of transitional cell carcinoma of the urinary bladder.
Shariat SF; Matsumoto K; Casella R; Jian W; Lerner SP
Eur Urol; 2005 Jul; 48(1):69-76. PubMed ID: 15967254
[TBL] [Abstract][Full Text] [Related]
52. [Influence of blood cells in urine samples on results of screening for urothelial carcinoma with NMP22 bladder chek].
Ueda Y; Kawaguchi R; Takiuchi H; Kokura K; Yoshimoto T; Mitsui Y; Suzuki T; Jun Q; Higuchi Y; Maruyama T; Kondoh N; Nozima M; Yamamoto S; Shima H
Hinyokika Kiyo; 2009 Feb; 55(2):71-4. PubMed ID: 19301610
[TBL] [Abstract][Full Text] [Related]
53. Comparative diagnostic value of urine cytology, UBC-ELISA, and fluorescence in situ hybridization for detection of transitional cell carcinoma of urinary bladder in routine clinical practice.
May M; Hakenberg OW; Gunia S; Pohling P; Helke C; Lübbe L; Nowack R; Siegsmund M; Hoschke B
Urology; 2007 Sep; 70(3):449-53. PubMed ID: 17688921
[TBL] [Abstract][Full Text] [Related]
54. NMP22 BladderChek Test: point-of-care technology with life- and money-saving potential.
Tomera KM
Expert Rev Mol Diagn; 2004 Nov; 4(6):783-94. PubMed ID: 15525221
[TBL] [Abstract][Full Text] [Related]
55. Nuclear matrix protein-22: a prospective evaluation in a population at risk for bladder cancer. Results from the UroScreen study.
Huber S; Schwentner C; Taeger D; Pesch B; Nasterlack M; Leng G; Mayer T; Gawrych K; Bonberg N; Pelster M; Johnen G; Bontrup H; Wellhäusser H; Bierfreund HG; Wiens C; Bayer C; Eberle F; Scheuermann B; Kluckert M; Feil G; Brüning T; Stenzl A;
BJU Int; 2012 Sep; 110(5):699-708. PubMed ID: 22313585
[TBL] [Abstract][Full Text] [Related]
56. Routine follow-up cystoscopy in detection of recurrence in patients being monitored for bladder cancer.
Raitanen MP; Leppilahti M; Tuhkanen K; Forssel T; Nylund P; Tammela T;
Ann Chir Gynaecol; 2001; 90(4):261-5. PubMed ID: 11820414
[TBL] [Abstract][Full Text] [Related]
57. A comparison of urinary nuclear matrix protein-22 and bladder tumour antigen tests with voided urinary cytology in detecting and following bladder cancer: the prognostic value of false-positive results.
Poulakis V; Witzsch U; De Vries R; Altmannsberger HM; Manyak MJ; Becht E
BJU Int; 2001 Nov; 88(7):692-701. PubMed ID: 11890239
[TBL] [Abstract][Full Text] [Related]
58. Evaluation of the telomeric repeat amplification protocol (TRAP) assay for telomerase as a diagnostic modality in recurrent bladder cancer.
Dalbagni G; Han W; Zhang ZF; Cordon-Cardo C; Saigo P; Fair WR; Herr H; Kim N; Moore MA
Clin Cancer Res; 1997 Sep; 3(9):1593-8. PubMed ID: 9815848
[TBL] [Abstract][Full Text] [Related]
59. Comparison of BTA stat and NMP22 tests in the detection of bladder cancer.
Oge O; Atsü N; Sahin A; Ozen H
Scand J Urol Nephrol; 2000 Dec; 34(6):349-51. PubMed ID: 11195897
[TBL] [Abstract][Full Text] [Related]
60. Comparison of screening methods in the detection of bladder cancer.
Ramakumar S; Bhuiyan J; Besse JA; Roberts SG; Wollan PC; Blute ML; O'Kane DJ
J Urol; 1999 Feb; 161(2):388-94. PubMed ID: 9915409
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]